Options and limits of surgery after pre-operative chemotherapy in breast cancer

Anticancer Research

Volumn 26, Issue 2 C, 2006, Pages 1677-1682

  Thomas, Anke ^a   Ohlinger, Ralf ^b   Hauschild, Maik ^a   Mustea, Alexander ^a   Blohmer, Jens Uwe ^c   Kümmel, Sherko ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF GREIFSWALD   (Germany)

^c St Gertrauden Hospital   (Germany)

Author keywords

Breast cancer; Breast conserving surgery; Primary chemotherapy; Review; Sentinel node

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE DERIVATIVE; AROMATASE INHIBITOR; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; MITOMYCIN C; MITOXANTRONE; PACLITAXEL; PREDNISOLONE; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB; VINCRISTINE;

AXILLARY LYMPH NODE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER REGRESSION; CANCER RELAPSE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; HUMAN; LYMPHADENECTOMY; MASTECTOMY; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; SENTINEL LYMPH NODE BIOPSY; SYSTEMIC THERAPY; TUMOR VOLUME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPH NODE EXCISION; MASTECTOMY, SEGMENTAL; PREOPERATIVE CARE;

EID: 33645757011     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (57)

1. Skipper HE: Kinetics of mammary tumor cell growth and implications for therapy. Cancer 28: 1479-1499, 1971.
2. Fisher B, Anderson S, Redmond CK et al: Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med 333: 1456-1461, 1995.
3. Early Breast Cancer Trialists' Collaborative Group: Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 352: 930-942, 1998.
4. Hortobagyi GN, Ames FC, Buzdar AU et al: Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy. Cancer 62: 2507-2516, 1988.
5. Gunduz N, Fisher B and Saffer EA: Effect of surgical removal on the growth and kinetics of residual tumor. Cancer Res 39: 3861-3865, 1979.
6. Fisher B, Gunduz N and Saffer EA: Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastases. Cancer Res 43: 1488-1492, 1983.
7. Goldie JH and Coldman AJ: A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 63: 1727-1733, 1979.
8. http: //leitlinien.net:
9. Mano MS and Amada A: Primary chemotherapy for breast cancer: the evidence and the future. Ann Oncol 75: 1161-1171, 2004.
10. Amat S, Bougnoux P, Penault-Llorca F et al: Neoadjuvant docetaxel for operable breast cancer induces a high pathological response and breast-conservation rate. Br J Cancer 88: 1339-1345, 2003.
11. Ezzat AA, Ibrahim EM, Ajarim DS et al: Phase II study of neoadjuvant paclitaxel and cisplatin for operable and locally advanced breast cancer: analysis of 126 patients. Br J Cancer 90: 968-974, 2004.
12. Jacquillat C, Weil M, Baillet F et al: Results of neoadjuvant chemotherapy and radiation therapy in the breast-conserving treatment of 250 patients with all stages of infiltrative breast cancer. Cancer 66: 119-129, 1990.
13. Bonadonna G, Valagussa P, Brambilla C et al: Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. J Clin Oncol 16: 93-100, 1998.
14. Smith IE, Walsh G, Jones A et al: High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer. J Clin Oncol 13: 424-429, 1995.
15. Chollet P, Charrier S, Brain E et al: Clinical and pathological response to primary chemotherapy in operable breast cancer. Eur J Cancer 33: 862-866, 1997.
16. Schwartz GF, Cantor RI and Biermann WA: Neoadjuvant chemotherapy before definitive treatment for stage III carcinoma of the breast. Arch Surg 122: 1430-1434, 1987.
17. Watatani M, Ueda K, Daito K et al: Clinical experience of weekly paclitaxel-based treatment as preoperative chemotherapy for patients with primary breast cancer. Breast Cancer 11: 187-193, 2004.
18. Espinosa E, Morales S, Borrega P et al: Docetaxel and high-dose epirubicin as neoadjuvant chemotherapy in locally advanced breast cancer. Cancer Chemother Pharmacol 54: 546-552, 2004.
19. Barni S, Piazza E, Frontini L et al: Single-agent epirubicin as primary chemotherapy in T2-T3, N0-N2, M0 breast carcinoma: 6-year follow-up. Oncology 67: 40-47, 2004.
20. Mauriac L, Durand M, Avril A et al: Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm. Results of a randomized trial in a single centre. Ann Oncol 2: 347-354, 1991.
21. Scholl SM, Fourquet A, Asselain B et al: Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6. Eur J Cancer 30A: 645-652, 1994.
22. Makris A, Powles TJ, Ashley SE et al: A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer. Ann Oncol 9: 1179-1184, 1998.
23. van der Hage JA, van de Velde CJ, Julien JP et al: Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 19: 4224-4237, 2001.
24. Jakesz R: Comparison of pre- versus postoperative chemotherapy in breast cancer patients: four-year results of Austrian Breast & Colorectal Cancer Study Group (ABCSG) Trial 7. Proc Am Soc Clin Oncol 20: abstract 125, 2001.
25. Wolmark N, Wang J, Mamounas E et al: Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr: 96-102, 2001.
26. Charfare H, Limongelli S and Purushotham AD: Neoadjuvant chemotherapy in breast cancer. Br J Surg 92: 14-23, 2005.
27. Bear HD, Anderson S, Brown A et al: The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 21: 4165-4174, 2003.
28. Eiermann W, Sabadell D, Baselga J et al: European cooperative trial in operable breast cancer (ECTO): no increased risk of local breast tumor recurrence (LBR) as first and only event after primary systemic therapy. Proc Am Soc Clin Oncol 22: abstract 37, 2003.
29. Dieras V, Fumoleau P, Romieu G et al: Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer. J Clin Oncol 22: 4958-4965, 2004.
30. Heys SD, Hutcheon AW, Sarkar TK et al: Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial. Clin Breast Cancer 3 Suppl 2: S69-74, 2002.
31. Buzdar AU, Singletary SE, Theriault RL et al: Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J Clin Oncol 17: 3412-3417, 1999.
32. Green MC, Buzdar AU, Smith T et al: Weekly paclitaxel followed by FAC as primary systemic therapy of operable breast cancer improves pathologic complete remission rates when compared to every 3-week paclitaxel therapy followed by FAC-final results of a prospective phase III randomised trial. Proc Am Soc Clin Oncol 22: abstract 135, 2002.
33. Minckwitz v G, Raab G, Caputo A et al: Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. J Clin Oncol 23 (12): 2676-2685, 2005.
34. Kaufmann M, von Minckwitz G, Smith R et al: International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. J Clin Oncol 21: 2600-2608, 2003.
35. Smith IE, A'Hern RP, Coombes GA et al: A novel continuous infusional 5-fluorouracil-based chemotherapy regimen compared with conventional chemotherapy in the neo-adjuvant treatment of early breast cancer: 5 year results of the TOPIC trial. Ann Oncol 15: 751-758, 2004.
36. Thomas E, Holmes FA, Smith TL et al: The use of alternate, non-cross-resistant adjuvant chemotherapy on the basis of pathologic response to a neoadjuvant doxorubicin-based regimen in women with operable breast cancer: long-term results from a prospective randomized trial. J Clin Oncol 22: 2294-2302, 2004.
37. Minckwitz v G, Blohmer JU, Raab G et al: In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study. Ann Oncol 16 (1): 56-63, 2005.
38. Fisher B, Bryant J, Wolmark N et al: Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16: 2672-2685, 1998.
39. Kuerer HM, Newman LA, Smith TL et al: Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17: 460-469, 1999.
40. Mauriac L, MacGrogan G, Avril A et al: Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonie Bordeaux Groupe Sein (IBBGS). Ann Oncol 10: 47-52, 1999.
41. Bonadonna G, Veronesi U, Brambilla C et al: Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst 82: 1539-1545, 1990.
42. Buzdar AU, Hunt K, Smith T et al: Significantly higher pathological complete remission (PCR) rate following neoadjuvant therapy with trastuzumab (H), paclitaxel (P), and anthracycline-containing chemotherapy (CT): initial results of a randomized trial in operable breast cancer (BC) with HER/2 positive disease. J Clin Oncol 22: abstract 520, 2004.
43. Coudert B, Arnould L, Moreau L et al: Final pathological complete response (pCr) of neoadjuvant (NA) trastuzumab (T) and docetaxel (D) chemotherapy (CT) in HER-2 positive (3+) localized breast cancer without possible primary conserving surgery. J Clin Oncol 22: abstract 2092, 2004.
44. Eiermann W, Paepke S, Appfelstaedt J et al: Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol 12: 1527-1532, 2001.
45. Dixon JM, Anderson TJ and Miller WR: Neoadjuvant endocrine therapy of breast cancer: a surgical perspective. Eur J Cancer 38: 2214-2221, 2002.
46. Milla-Santos A, Milla L, Calvo N et al: Anastrozole as neoadjuvant therapy for patients with hormone-dependent, locally-advanced breast cancer. Anticancer Res 24: 1315-1318, 2004.
47. Semiglazov VF, Ivanov VG, Semiglazov VV ZE, Kletzel AA, Melnikova OA, Topuzov EE, Paltuev RM, Bozhok AA and Dashian GA: Neoadjuvant endocrine therapy vs chemotherapy for postmenopausal ER-positive breast cancer patients. J Clin Oncol 22: abstract 519, 2004.
48. Bauerfeind IG, Nestle-Kraemling C, Kahlert S et al: Surgical management of patients following preoperative chemotherapy for primary breast cancer; results from a prospective randomised AGO protocol with dose dense paclitaxel and epirubicin chemotherapy. Proc Am Soc Clin Oncol 22: abstract 84, 2003.
49. Veronesi U, Bonadonna G, Zurrida S et al: Conservation surgery after primary chemotherapy in large carcinomas of the breast. Ann Surg 222: 612-618, 1995.
50. Mamounas EP: Neoadjuvant chemotherapy for operable breast cancer: is this the future? Clin Breast Cancer 4 Suppl 1: S10-19, 2003.
51. Curran D, van Dongen JP, Aaronson NK et al: Quality of life of early-stage breast cancer patients treated with radical mastectomy or breast-conserving procedures: results of EORTC Trial 10801. The European Organization for Research and Treatment of Cancer (EORTC), Breast Cancer Co-operative Group (BCCG). Eur J Cancer 34: 307-314, 1998.
52. Rouzier R, Extra JM, Klijanienko J et al: Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes. J Clin Oncol 20: 1304-1310, 2002.
53. Kuerer HM, Newman LA, Buzdar AU et al: Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease-free survival in patients with locally advanced breast cancer. Am J Surg 176: 502-509, 1998.
54. Buchholz TA, Strom EA, Perkins GH et al: Controversies regarding the use of radiation after mastectomy in breast cancer. Oncologist 7: 539-746, 2002.
55. Pusztai L, Gregory BW, Baggerly KA et al: Pharmacoproteomic analysis of prechemotherapy and postchemotherapy plasma samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast carcinoma. Cancer 100: 1814-1822, 2004.
56. Cleator SJ, Powles TJ, Smith IE et al: Microarray assessment of chemotherapy-induced expression changes in breast cancers as a predictor of clinical response. J Clin Oncol 22: abstract 1021, 2004.
57. Hannemann J, Oosterkamp HM, Bosch CAJ LC, Witteveen A, Velds A, Rutgers EJTH, Rodenhuis S and Van de Vijver M: Netherlands Cancer Institute: Changes in gene expression profiling due to primary chemotherapy in patients with locally advanced breast cancer. J Clin Oncol 22: abstract 502, 2004.